论文部分内容阅读
肺动脉高压是一类以小肺动脉血管重构为特征的恶性肺血管疾病,肺血管阻力进行性升高最终导致右心衰竭死亡。肺动脉高压的药物治疗主要针对前列环素、内皮素、一氧化氮三个靶点。他达那非(Tadalafil)是一种口服、长效、选择性5-型磷酸二酯酶抑制剂,增加环磷酸鸟苷(cGMP)浓度,通过一氧化氮途径起到治疗作用。PHIRST临床试验证实肺动脉高压患者每日一次口服他达那非40mg,能够提高6分钟步行距离,减少临床恶化。本文就他达那非治疗肺动脉高压研究新进展作一综述。
Pulmonary hypertension is a class of malignant pulmonary vascular disease characterized by remodeling of small pulmonary arteries, which leads to the death of right heart failure. Pulmonary hypertension drug treatment mainly targeting prostacyclin, endothelin, nitric oxide three targets. Tadalafil is an oral, long-acting, selective 5-type phosphodiesterase inhibitor that increases the concentration of cGMP and acts through a nitric oxide pathway. PHIRST clinical trial confirmed that patients with pulmonary hypertension once daily oral tadalafil 40mg, can increase 6-minute walking distance, reduce clinical deterioration. This article reviews the recent advances in the treatment of pulmonary hypertension in tadalafil.